博雅生物(300294.SZ)擬收購羅益生物11.68%股權
格隆匯12月20日丨博雅生物(300294.SZ)公佈,經公司第六屆董事會第二十八次會議、第六屆監事會第二十五次會議,審議通過了《關於公司支付現金購買資產的議案》,公司擬以現金對價8850.00萬元收購王勇持有的羅益(無錫)生物製藥有限公司(“羅益生物”)5.90%的股權,擬以現金對價8670.00萬元收購上海懿仁投資合夥企業(有限合夥)(“上海懿仁”)持有的羅益生物5.78%的股權。
羅益生物專注於疫苗的研發、生產和銷售,主要產品包括A羣C羣腦膜炎球菌多糖結合疫苗(MCV2)和雙價腎綜合徵出血熱滅活疫苗(Vero細胞),其中A羣C羣腦膜炎球菌多糖結合疫苗用於預防兒童流行性腦脊髓膜炎,雙價腎綜合徵出血熱滅活疫苗(Vero細胞)用於預防腎綜合徵出血熱。此外,羅益生物儲備的新產品A羣C羣腦膜炎球菌多糖-b型流感嗜血桿菌結合疫苗(AC-Hib聯合疫苗)和b型流感嗜血桿菌結合疫苗(Hib疫苗)處於三期臨牀階段、傷寒甲型副傷寒結合疫苗處於一期臨牀試驗階段。
自成立以來,羅益生物主營業務未發生重大變化,一直從事疫苗產品研發、生產和銷售業務,其中核心產品A羣C羣腦膜炎球菌多糖結合疫苗是國內首款凍幹型A羣C羣腦膜炎球菌多糖結合疫苗,與液體制劑相比,凍幹型疫苗不含防腐劑和佐劑,同時更為穩定,與市場同類型產品相比,免疫針次少,是國內唯一在12月齡基礎免疫僅需2針的產品,與《國家免疫規劃兒童免疫程序(2016版)》一類流腦疫苗免疫程序相符,便於產品替代。
董事會認為:此次收購羅益生物股權,公司業務將延伸至疫苗領域,業務規模將得以擴大,盈利能力和抗風險能力也將得以提升,有利於增強上市公司的核心競爭力,進而提升上市公司價值,有利於從根本上保護公司及股東特別是中小股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.